title: Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.
abstract: We conducted a retrospective collaborative study to cytogenetically characterize splenic marginal zone lymphoma (SMZL) and ascertain the prognostic value of chromosomal aberrations. Of 330 cases, 72% displayed an aberrant karyotype, 53% were complex, and 29% had a single aberration. The predominant aberrations were gains of 3/3q and 12q, deletions of 7q and 6q and translocations involving 8q/1q/14q. CD5 expression was detected in 39 of 158 cases (25%). The cytogenetic makeup of the CD5(+) group differed significantly from that of the CD5(-) group. Cases with unmutated IGHV were significantly associated with deletions of 7q and TP53. A strong association was noted between usage of the IGVH1-2 and deletion 7q, 14q alterations, and abnormal karyotype. On univariate analysis, patients with more than or equal to 2 aberrations, 14q alterations, and TP53 deletions had the shortest survival; 7q deletion did not affect survival. On multivariate analysis, cytogenetic aberrations did not retain prognostic significance; the parameters negatively affecting survival were hemoglobin and age. In conclusion, the cytogenetic profile of SMZL is distinct from other B-cell lymphomas. Complexity of the karyotype, 14q aberrations, and TP53 deletions are poor prognostic indicators and may be considered together with other clinicobiologic parameters to ascertain the prognosis of SMZL.
authors.affiliation: Hospital del Mar, IMAS, Barcelona, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Salido
authors.forename: Cristina
authors.initials: C
authors.lastname: Baró
authors.forename: David
authors.initials: D
authors.lastname: Oscier
authors.forename: Kostas
authors.initials: K
authors.lastname: Stamatopoulos
authors.forename: Judith
authors.initials: J
authors.lastname: Dierlamm
authors.forename: Estela
authors.initials: E
authors.lastname: Matutes
authors.forename: Alexandra
authors.initials: A
authors.lastname: Traverse-Glehen
authors.forename: Francoise
authors.initials: F
authors.lastname: Berger
authors.forename: Pascale
authors.initials: P
authors.lastname: Felman
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.forename: Stefan
authors.initials: S
authors.lastname: Gesk
authors.forename: Anastasia
authors.initials: A
authors.lastname: Athanasiadou
authors.forename: Zadie
authors.initials: Z
authors.lastname: Davis
authors.forename: Anne
authors.initials: A
authors.lastname: Gardiner
authors.forename: Fuensanta
authors.initials: F
authors.lastname: Milla
authors.forename: Ana
authors.initials: A
authors.lastname: Ferrer
authors.forename: Manuela
authors.initials: M
authors.lastname: Mollejo
authors.forename: Maria José
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: Lourdes
authors.initials: L
authors.lastname: Florensa
authors.forename: Blanca
authors.initials: B
authors.lastname: Espinet
authors.forename: Elisa
authors.initials: E
authors.lastname: Luño
authors.forename: Iwona
authors.initials: I
authors.lastname: Wlodarska
authors.forename: Gregor
authors.initials: G
authors.lastname: Verhoef
authors.forename: Marta
authors.initials: M
authors.lastname: García-Granero
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
authors.forename: Theodora
authors.initials: T
authors.lastname: Papadaki
authors.forename: Sergio
authors.initials: S
authors.lastname: Serrano
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
authors.forename: Francesc
authors.initials: F
authors.lastname: Solé
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D016158:Genes, p53; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D018442:Lymphoma, B-Cell, Marginal Zone / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012189:Retrospective Studies; D013160:Splenic Neoplasms / Q000235:genetics* / Q000473:pathology; D015996:Survival Rate
chemical_list: D004273:DNA, Neoplasm; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region